The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Thermosensitive liposomes for localized delivery and triggered release of chemotherapy
Open accessAbstract
Liposomes are a promising class of nanomedicine with the potential to provide site-specific chemotherapy, thus improving the quality of cancer patient care. First-generation liposomes have emerged as one of the first nanomedicines used clinically for localized delivery of chemotherapy. Second-generation liposomes, i.e. stimuli-responsive liposomes, have the potential to not only provide site-specific chemotherapy, but also triggered drug release and thus greater spatial and temporal control of therapy. Temperature-sensitive liposomes are an especially attractive option, as tumors can be heated in a controlled and predictable manner with external energy sources. Traditional thermosensitive liposomes are composed of lipids that undergo a gel-to-liquid phase transition at several degrees above physiological temperature. More recently, temperature-sensitization of liposomes has been demonstrated with the use of lysolipids and synthetic temperature-sensitive polymers. The design, drug release behavior, and clinical potential of various temperature-sensitive liposomes, as well as the various heating modalities used to trigger release, are discussed in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“This phenomenon – whereby macromolecular drugs and nanomedicines of a certain size will tend to accumulate in tumor tissue more than in healthy tissue – is known as the enhanced permeability and retention (EPR) effect [13].”
BackgroundRenal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476 · cited 1×
“Delivery vehicles large enough (>5–6 nm [25]) to escape renal clearance but small enough (<150 nm, in the case of neutral or slightly negatively charged lipid-based carriers [26,27]) to exploit this EPR effect can be used to increase drug bioavailability and reduce off-target toxicities associated with systemic admini…”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“Delivery vehicles large enough (>5–6 nm [25]) to escape renal clearance but small enough (<150 nm, in the case of neutral or slightly negatively charged lipid-based carriers [26,27]) to exploit this EPR effect can be used to increase drug bioavailability and reduce off-target toxicities associated with systemic admini…”
BackgroundTargeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“These toxic effects restrict the dosages administered to patients, and cancers that survive these lower dosages oftentimes develop a resistance to chemotherapy, making it much more difficult to eradicate the tumors and save the patient [3].”
BackgroundNanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Folkman, J., & Shing, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49853-0 · Cited by 2,654
Cited by
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Liposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
Rational Design of Cancer Nanomedicine: Nanoproperty Integration and Synchronization
Sun, Q., Zhou, Z., Qiu, N., & Shen, Y. (2017) · Advanced Materials · doi:10.1002/adma.201606628 · Cited by 1,058
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
Large, D. E., Abdelmessih, R. G., Fink, E. A., & Auguste, D. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113851 · Cited by 877
Magnetic nanoparticle-based therapeutic agents for thermo-chemotherapy treatment of cancer
Hervault, A., & Thanh, N. T. K. (2014) · Nanoscale · doi:10.1039/c4nr03482a · Cited by 585
Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine
Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky‐Roitman, J., Lammers, T., & Schroeder, A. (2020) · Advanced Materials · doi:10.1002/adma.201901989 · Cited by 496
Liposomal Delivery Systems: Design Optimization and Current Applications
Abu Lila, A. S., & Ishida, T. (2017) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00624 · Cited by 382
Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery
Majumder, J., & Minko, T. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1828339 · Cited by 348
Thermosensitive liposomal drug delivery systems: state of the art review
Hossann, M., Kneidl, B., Peller, M., Lindner, L., & Winter, G. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s49297 · Cited by 342
Li, J., Yu, X., Jiang, Y., He, S., Zhang, Y., Luo, Y., & Pu, K. (2021) · Advanced Materials · doi:10.1002/adma.202003458 · Cited by 340
Liposomes for Tumor Targeted Therapy: A Review
Wang, S., Chen, Y., Guo, J., & Huang, Q. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032643 · Cited by 315
Lipid-based nanovesicles for nanomedicine
Grimaldi, N., Andrade, F., Segovia, N., Ferrer-Tasies, L., Sala, S., Veciana, J., & Ventosa, N. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00409a · Cited by 309
Boissenot, T., Bordat, A., Fattal, E., & Tsapis, N. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.026 · Cited by 264
Liposomes in Cancer Therapy: How Did We Start and Where Are We Now
Fulton, M. D., & Najahi-Missaoui, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076615 · Cited by 258
Pande, S. (2023) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2023.2247036 · Cited by 258
Drug delivery vehicles on a nano-engineering perspective
Felice, B., Prabhakaran, M. P., Rodríguez, A. P., & Ramakrishna, S. (2014) · Materials Science and Engineering: C · doi:10.1016/j.msec.2014.04.049 · Cited by 253
Lv, Y., Xu, C., Zhao, X., Lin, C., Yang, X., Xin, X., Zhang, L., Qin, C., Han, X., Yang, L., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b08051 · Cited by 235
Liposomal delivery of natural product: A promising approach in health research
Islam Shishir, M. R., Karim, N., Gowd, V., Zheng, X., & Chen, W. (2019) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2019.01.013 · Cited by 178
Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems
Gyanani, V., Haley, J. C., & Goswami, R. (2021) · Pharmaceuticals · doi:10.3390/ph14090835 · Cited by 118
Ultrasonically triggered drug delivery: Breaking the barrier
Husseini, G. A., Pitt, W. G., & Martins, A. M. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.07.051 · Cited by 87
Li, B., Wang, Y., Gao, D., Ren, S., Li, L., Li, N., An, H., Zhu, T., Yang, Y., Zhang, H., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202010757 · Cited by 41
Thermoresponsive M1 macrophage-derived hybrid nanovesicles for improved in vivo tumor targeting
Barone, A., Zimbo, A. M., d’Avanzo, N., Tolomeo, A. M., Ruga, S., Cardamone, A., Celia, C., Scalise, M., Torella, D., La Deda, M., et al. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01378-9 · Cited by 22
Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases
Neupane, Y. R., Mahtab, A., Siddiqui, L., Singh, A., Gautam, N., Rabbani, S. A., Goel, H., & Talegaonkar, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200523174108 · Cited by 21
Metadata
- Authors
- Ta, T., & Porter, T. M.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 169
- Issue
- 1-2
- Pages
- 112-125
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2000568918
- Cited by
- 403
- References
- 122
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.